Clinical Trial

Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC

Study acronym: PRO-RIC
Recruiting
View on ClinicalTrials.gov →
Summary
This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft failure and to aid in immune reconstitution following hematopoietic stem cell transplantation.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-08-25; most recent amendment 2026-01-12.
Trial Details
NCT Number NCT04528355
Lead Sponsor Paul Szabolcs
Conditions Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions
Enrollment 50 participants
Start Date 2020-08-20
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-13